The GLP-1 battle heats up with new preliminary data from Eli Lilly showing that patients using its weight loss drug Zepbound lost more weight on average in 72 weeks — 20.2% of their body weight — than those on Novo Nordisk’s Wegovy, who lost only 13.7%.
Novo’s Wegovy currently has a greater market share than Eli Lilly’s Zepbound, but if this new data holds up, payers may tip the balance in favor of the Indianapolis-based pharma company in the future.
NEMT Partner Guide: Why Payers and Providers Should Choose MediDrive’s TMS
Alan Murray on improving access for medical transportation.
Read the full article here.